London—Dentons has advised Westhouse Securities and Beaufort Securities as joint brokers on a £20 million fundraising for Advanced Oncotherapy.

Advanced Oncotherapy develops next generation proton therapy systems for cancer treatment. Its fundraising will continue the development of its LIGHT (Linac for Image Guided Hadron Therapy) systems with the first unit expected to be installed in Harley Street, London, by the end of 2016. Patients are expected to begin treatment in 2017.

Dentons also advised Westhouse Securities in its capacity as agent and broker to European Islamic Investment Bank PLC on a tender offer to its shareholders to purchase up to eight million shares, representing around 21% of its issued share capital at £2.50 per share.

The Dentons team was supported by Rachael Dixon (Associate, Corporate) on Advanced Oncotherapy and Simon Mitchell (Managing Associate, Corporate) on Westhouse Securities.

Dentons commented, "We have a strong relationship with Westhouse and were pleased to have worked with them and Beaufort in connection with this successful secondary fundraising for Advanced Oncotherapy and on the tender offer for European Islamic Investment Bank PLC. Our equity capital markets group continues to demonstrate its strength by acting for NOMADs, as well as issuers, following the recent successful AIM IPOs of Marshall Motor Holdings Plc and Bilby Plc."

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com